Milanda coated tablets 3 mg/0.03 mg. №21


Oral contraception.



Milanda composition
The main active ingredients of the drug are ethinylestradiol and drospirenone. As an auxiliary component are used: lactose monohydrate, corn starch, pregelatinized starch, crospovidone, povidone, polysorbate, magnesium stearate, etc.

Release form
Produced in tablet form. The tablets contain 3 mg of drospirenone and 0.03 mg of ethinyl estradiol.

Pharmacological properties
Milanda belongs to the group of oral contraceptive drugs, includes hormones of the gonads, their fixed estrogen-progestin combinations.
It is a hormonal drug that contains ethinylestradiol and drospirenone (analogue of natural progestogen).
The contraceptive effect of this drug is based on the interaction of various properties of its constituent substances, the most important of which is the ability to inhibit ovulation and produce a qualitative effect on the endometrium of the uterus.
Drospirenone, when used in therapeutic doses, has antiandrogenic and mild antimineralocorticoid properties.
It lacks any estrogenic, glucocorticoid and antiglucocorticoid activity, which provides drospirenone with a pharmacological profile that is very similar to that of the naturally occurring hormone progesterone.
Weak anti-mineralocorticoid properties lead to a weak anti-mineralocorticoid effect.

Milanda is used as an oral hormonal contraceptive.
In addition to the properties of contraception, it has other properties. In particular, it produces an antiandrogenic effect, as a result, it has an effect on androgenic alopecia, acne, seborrhea, hormone-dependent fluid retention in the body.
Also has properties of treating the symptoms of premenstrual dysphoric disorder in women who use oral contraception.
Ethinylestradiol, which is part of the drug, is able to prevent the occurrence of osteoporosis by affecting osteoclasts. It also has a beneficial effect on the skin, slows down the formation of wrinkles on it, reduces the concentration of glucose and insulin in the blood.
Drospirenone is a progestogen. It counteracts water retention in the body, and as a result, the occurrence of arterial hypertension, weight gain, breast tenderness, edema.
The drug is also able to normalize lipid metabolism, reduce blood cholesterol levels. This medicine can also prevent the appearance of malignant neoplasms.

It is not applied if the patient has hypersensitivity (allergy) to one of the components that make up the drug.
This medicinal product should not be used in patients who have:

  • vaginal bleeding;
  • oncological disease, benign tumor;
  • hepatic, renal failure;
  • arterial / venous thrombosis, thromboembolism;
  • acute violation of cerebral circulation;
  • severe arterial hypertension;
  • pancreatitis, liver tumors;
  • obesity;
  • diabetes;
  • migraine.

Application during pregnancy and lactation
This drug is contraindicated for use during pregnancy and lactation.

Method of administration and dosage
Milanda is taken 1 tablet a day, at the same time of the day. When taking, you should adhere to the sequence indicated on the back of the blister.
The tablets are taken in a row for 21 days. Each next package starts 7 days after the previous one ended.
Bleeding, similar to menstruation, begins 2-3 days after the end of the pack, and does not have to end before the next pack starts.
If the appointment is missed, then the next pill should be taken as soon as you remember about it. The next pill is taken the next day at the usual time. Moreover, if the break was less than 24 hours, then the contraceptive properties of the drug are not reduced. If the break is more than 24 hours, then the contraceptive effect may be reduced.
If an abortion is performed in the first trimester, then the drug is taken on the day of the operation.
If the abortion was performed in the second trimester of pregnancy, or the woman wants to start taking oral contraceptives after childbirth, then the reception begins on the 21-28th day.
Contraceptive effect is not guaranteed in the first week of admission. Therefore, these days, barrier methods of contraception should be used.
The break in admission can be less than 4, but not more than seven days.

Overdose with this drug has not yet been observed and described.
Theoretically, an overdose of this drug can cause:

  • dyspepsia;
  • nausea;
  • vomiting;
  • vaginal bleeding.

Symptomatic treatment is recommended. No antidote has yet been identified.

Side effects
At the very beginning of replacement therapy with this drug, bleeding may occur, smearing vaginal discharge of a woman, pain in the mammary glands.
Adverse reactions have been observed with this drug:

  • anemia, anorexia, increased appetite, changes in body weight, constipation;
  • irritability, depression, emotional instability, tachycardia, phlebitis;
  • visual impairment, tinnitus, tremor, vertigo, candidal stomatitis;
  • thromboembolism, arterial hypertension, varicose veins, thrombophlebitis, venous thrombosis;
  • shortness of breath, abdominal pain, nausea, dyspepsia, vomiting, xerostomia;
  • stones in the gallbladder, cholecystitis;
  • hirsutism, alopecia, acne;
  • urinary tract infections, dysmenorrhea, uterine fibroids, benign tumors in the mammary glands, uterus, cervix;
  • swelling, chest pain, chills;
  • chloasma, purpura, erythema multiforme.

If you have any unusual side effects as a result of taking this drug, you should consult your doctor about possible changes in the treatment regimen.

Storage conditions and periods
Stored for up to 3 years at a temperature not exceeding 25 ° C.